Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,544,340
  • Shares Outstanding, K 34,500
  • Annual Sales, $ 333,760 K
  • Annual Income, $ 4,660 K
  • 36-Month Beta 0.40
  • Price/Sales 14.09
  • Price/Cash Flow 1,133.70
  • Price/Book 11.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.11
  • Number of Estimates 3
  • High Estimate 0.13
  • Low Estimate 0.09
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.12 +9.66%
on 11/20/18
160.50 -17.93%
on 11/08/18
-24.76 (-15.82%)
since 11/07/18
3-Month
120.12 +9.66%
on 11/20/18
160.50 -17.93%
on 11/08/18
-10.38 (-7.30%)
since 09/07/18
52-Week
82.55 +59.56%
on 01/08/18
167.35 -21.29%
on 06/01/18
+31.32 (+31.20%)
since 12/07/17

Most Recent Stories

More News
In Search of an Earnings Beat? Play These Top 5 Stocks

These top-ranked stocks may surpass bottom-line estimates in their next release.

S : 6.01 (-1.96%)
PEN : 131.72 (-3.37%)
ANF : 18.76 (-2.90%)
PCRX : 46.23 (-3.97%)
CRM : 135.95 (-4.30%)
Notable Two Hundred Day Moving Average Cross - PEN

In trading on Thursday, shares of Penumbra Inc crossed below their 200 day moving average of $136.89, changing hands as low as $131.40 per share. Penumbra Inc shares are currently trading off about 4.4%...

PEN : 131.72 (-3.37%)
Penumbra, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BMO Prescriptions for Success Healthcare Conference in New York, NY on Wednesday, December 12, 2018.

PEN : 131.72 (-3.37%)
Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Resonant Inc. (NASDAQ:RESN),...

LIVN : 94.84 (-3.75%)
RESN : 1.60 (-2.44%)
STZ : 188.61 (-1.11%)
PEN : 131.72 (-3.37%)
MASI : 105.30 (-2.54%)
TTPH : 1.65 (-4.62%)
Is Penumbra (PEN) Stock Outpacing Its Medical Peers This Year?

Is (PEN) Outperforming Other Medical Stocks This Year?

PEN : 131.72 (-3.37%)
Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty

Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty

FRSH : 5.13 (-0.97%)
AEE : 70.42 (+0.37%)
ABR : 11.80 (-0.08%)
TSLA : 357.96 (-1.40%)
PEN : 131.72 (-3.37%)
5 Low-Beta Stocks to Beat Market Volatility

We have developed a strategy to show that securities with lower volatility than the market can generate lucrative returns.

FRSH : 5.13 (-0.97%)
AEE : 70.42 (+0.37%)
ABR : 11.80 (-0.08%)
TSLA : 357.96 (-1.40%)
PEN : 131.72 (-3.37%)
Is Penumbra (PEN) Outperforming Other Medical Stocks This Year?

Is (PEN) Outperforming Other Medical Stocks This Year?

PEN : 131.72 (-3.37%)
DexCom (DXCM) Catches Eye: Stock Jumps 8.8%

DexCom (DXCM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

PEN : 131.72 (-3.37%)
DXCM : 121.41 (-6.23%)
Penumbra (PEN) Surpasses Q3 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 466.67% and 9.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

PEN : 131.72 (-3.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PEN with:

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

2nd Resistance Point 139.95
1st Resistance Point 135.84
Last Price 131.72
1st Support Level 128.70
2nd Support Level 125.68

See More

52-Week High 167.35
Fibonacci 61.8% 134.96
Last Price 131.72
Fibonacci 50% 124.95
Fibonacci 38.2% 114.94
52-Week Low 82.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar